CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.

@article{Aklillu2007CYP2D6AD,
  title={CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.},
  author={Eleni Aklillu and Werner Kalow and L{\'a}szl{\'o} Endr{\'e}nyi and Patricia L Harper and Jun Miura and Vural Ozdemir},
  journal={Pharmacogenetics and genomics},
  year={2007},
  volume={17 11},
  pages={989-93}
}
OBJECTIVES We observed that CYP2D6 contributes to pharmacodynamic tissue sensitivity to perphenazine as measured by the areas under the curve (AUCs) expressed as a ratio (prolactin-AUC0-6/perphenazine-AUC0-6) in Chinese Canadians [Pharmacogenetics and Genomics 2007; 17:339-347]. As genetic heterogeneity in drug targets can influence drug response, we sought to further evaluate the contribution of CYP2D6 to pharmacodynamic sensitivity in our previous study sample in tandem with DRD2, the primary… CONTINUE READING